3 completed, 2 recruiting, 1 active not recruiting, 1 unknown. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Diabetic Peripheral Neuropathic Pain: new trials by email Literature Review of Diabetic Peripheral Neuropathic Pain trials Research Report on Diabetic Peripheral Neuropathic Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy Suzetrigine, Placebo (matched to SUZ) - Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 734 | 2025-11-21 | 2026-07-20 |
| Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) Suzetrigine - Diabetic Peripheral Neuropathic Pain | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 455 | 2024-12-18 | 2026-10-30 |
| Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy Suzetrigine, Placebo (matched to SUZ), Pregabalin - Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 1100 | 2024-10-01 | 2026-10-15 |
| To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain HSK16149 20mg BID, HSK16149 40mg BID, HSK16149 60mg BID - Diabetic Peripheral Neuropathic Pain | Phase 2 / Phase 3 | Unknown | Haisco Pharmaceutical Group Co., Ltd. | 687 | 2020-12-02 | 2020-12-01 |
| A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain Mirogabalin, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 3 | Completed | Daiichi Sankyo Co., Ltd. | 393 | 2019-09-18 | 2022-10-24 |
| DS-5565 Phase III Study for Renal Impairment in Japanese Subjects DS-5565 - Diabetic Peripheral Neuropathic Pain, Post-herpetic Neuralgia | Phase 3 | Completed | Daiichi Sankyo Co., Ltd. | 35 | 2015-12-01 | 2021-05-13 |
| DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain DS-5565, placebo - Diabetic Peripheral Neuropathic Pain | Phase 3 | Completed | Daiichi Sankyo Co., Ltd. | 854 | 2015-01-01 | 2020-11-02 |
Neuralgia, Postherpetic (1) · Renal Insufficiency (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nervous System Diseases (1) · Neuralgia (1) · Neurologic Manifestations (1) · Neuromuscular Diseases (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Peripheral Nervous System Diseases (1) · Signs and Symptoms (1) · Urogenital Diseases (1) · Urologic Diseases (1)
mirogabalin (3) · Pregabalin (2) · BID protein, human (1)
Daiichi Sankyo Co., Ltd. (3) · Vertex Pharmaceuticals Incorporated (3) · Haisco Pharmaceutical Group Co., Ltd. (1)
United States (3) · China (2) · Japan (2)
PMID 32765056, PMID 34059327, PMID 38896199, PMID 39158916, PMID 40377855, PMID 41384808, PMID 42249666